Search results
Showing 391 to 405 of 971 results for death
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)
Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.
View recommendations for IPG382Show all sections
Sections for IPG382
Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates (IPG246)
Evidence-based recommendations on hybrid procedure for interim management of hypoplastic left heart syndrome in neonates. This involves placing bands around the branches of the pulmonary artery and inserting stents to keep the ductus arteriosus open.
View recommendations for IPG246Show all sections
Sections for IPG246
This quality standard covers preventing and identifying alcohol problems in the community. It includes policy and practice approaches to prevent harmful alcohol use in adults, young people and children. It is particularly relevant to local authorities, the police, and schools and colleges. It describes high-quality care in priority areas for improvement.
View quality statements for QS83Show all sections
Sections for QS83
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Intrapartum care: existing medical conditions and obstetric complications (QS192)
This quality standard covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. It also covers women who have had no antenatal care. It describes high-quality care in priority areas for improvement. It does not cover the antenatal and postnatal care of pregnant women with mental health conditions, hypertension in pregnancy, diabetes in pregnancy or the organisation of care for pregnant women with complex social factors.
View quality statements for QS192Show all sections
Sections for QS192
- Quality statements
- Quality statement 1: Involving women in care planning
- Quality statement 2: Composition of the multidisciplinary team
- Quality statement 3: Heart disease – risk assessment
- Quality statement 4: Assessment and antibiotic treatment for suspected sepsis
- Quality statement 5: Women with no antenatal care
- Update information
- About this quality standard
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
This guidance has been updated and replaced by NICE guideline CG189.
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.
Emergency and acute medical care in over 16s: service delivery and organisation (NG94)
This guideline covers organising and delivering emergency and acute medical care for people aged over 16 in the community and in hospital. It aims to reduce the need for hospital admissions by giving advanced training to paramedics and providing community alternatives to hospital care. It also promotes good-quality care in hospital and joint working between health and social services.
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.